CircRNA_100920 enhanced oncolytic adenovirus therapy in colon cancer by suppressing IFN-γ expression

Colon cancer (CRC) is one of the leading causes of tumor lethality in the world. CRC is mostly diagnosed at advanced stages of disease, and chemotherapy is one of the major options in treating the advanced CRC patients. However, the development of multi-drug resistance has become the obstacle to an effective control of CRC clinically. Thus, it is essentially significant for scientists and medical doctors to explore new strategies for CRC therapy. CircRNA_100920 expression was upregulated in CRC tissues and cells. Knockdown of circRNA_100920 inhibited cell proliferation in CRC cells. Clinically, circRNA_100920 was associated with survival rate, metastasis, TNM stage and tumor size. Notably, circRNA_100920 could become a potential biomarker by the receiver operating characteristic curve analysis. In addition, circRNA_100920 enhanced oncolytic adenovirus therapy in colon cancer by suppressing IFN-gamma expression. CircRNA_100920, as a biomarker, may participate in the diagnosis, treatment, and prognosis of CRC.

Automated summary

Colon cancer is a leading cause of tumor lethality worldwide, and the development of multidrug resistance poses challenges for effective control. The upregulation of circRNA_100920 in CRC tissues and cells suggests its potential as a biomarker for diagnosis, treatment, and prognosis of CRC. Further research on circRNA_100920 may lead to new therapeutic strategies for CRC.